- Home
- ATNI vs AVIR Comparison
ATNI vs AVIR Comparison
Compare ATNI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATNI | AVIR |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.5M | 434.5M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATNI | AVIR |
|---|---|---|
| Price | $28.15 | $4.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 52.2K | ★ 281.1K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ 34.29 | 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $727,975,000.00 | $351,367,000.00 |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $1.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.86 | $2.78 |
| 52 Week High | $30.45 | $6.45 |
Technical Indicators
Market Signals| Indicator | ATNI | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 46.12 |
| Support Level | $25.06 | $4.10 |
| Resistance Level | $29.17 | $4.80 |
| Average True Range (ATR) | 1.14 | 0.21 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 80.13 | 55.74 |
Price Performance
Historical ComparisonAbout ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.